Precision medicine in pancreatic cancer: treating every patient as an exception

Siegel, 2019, Cancer statistics, 2019, CA Cancer J Clin, 69, 73, 10.3322/caac.21551 He, 2014, 2564 resected periampullary adenocarcinomas at a single institution: trends over three decades, HPB (Oxford), 16, 83, 10.1111/hpb.12078 Oettle, 2013, Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial, JAMA, 310, 1473, 10.1001/jama.2013.279201 Conroy, 2018, FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer, N Engl J Med, 379, 2395, 10.1056/NEJMoa1809775 Ying, 2012, Developments in metastatic pancreatic cancer: is gemcitabine still the standard?, World J Gastroenterol, 18, 736, 10.3748/wjg.v18.i8.736 Moore, 2007, Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group, J Clin Oncol, 25, 1960, 10.1200/JCO.2006.07.9525 Conroy, 2011, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, N Engl J Med, 364, 1817, 10.1056/NEJMoa1011923 Von Hoff, 2013, Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine, N Engl J Med, 369, 1691, 10.1056/NEJMoa1304369 Jones, 2008, Core signaling pathways in human pancreatic cancers revealed by global genomic analyses, Science, 321, 1801, 10.1126/science.1164368 Biankin, 2012, Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes, Nature, 491, 399, 10.1038/nature11547 Bailey, 2016, Genomic analyses identify molecular subtypes of pancreatic cancer, Nature, 531, 47, 10.1038/nature16965 Witkiewicz, 2015, Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets, Nat Commun, 6, 10.1038/ncomms7744 Sidaway, 2017, Pancreatic cancer: TCGA data reveal a highly heterogeneous disease, Nat Rev Clin Oncol, 14, 648 Chen, 2018, Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor, Cell, 172, 578, 10.1016/j.cell.2018.01.006 Lito, 2016, Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism, Science, 351, 604, 10.1126/science.aad6204 Patricelli, 2016, Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state, Cancer Discov, 6, 316, 10.1158/2159-8290.CD-15-1105 Collisson, 2019, Molecular subtypes of pancreatic cancer, Nat Rev Gastroenterol Hepatol, 16, 207, 10.1038/s41575-019-0109-y Collisson, 2011, Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy, Nat Med, 17, 500, 10.1038/nm.2344 Moffitt, 2015, Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma, Nat Genet, 47, 1168, 10.1038/ng.3398 Connor, 2019, Integration of genomic and transcriptional features in pancreatic cancer reveals increased cell cycle progression in metastases, Cancer Cell, 35, 267, 10.1016/j.ccell.2018.12.010 Aung, 2018, Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial, Clin Cancer Res, 24, 1344, 10.1158/1078-0432.CCR-17-2994 Lomberk, 2018, Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes, Nat Commun, 9, 10.1038/s41467-018-04383-6 2017, Integrated genomic characterization of pancreatic ductal adenocarcinoma, Cancer Cell, 32, 185, 10.1016/j.ccell.2017.07.007 Sato, 2004, Gene expression profiling of tumor-stromal interactions between pancreatic cancer cells and stromal fibroblasts, Cancer Res, 64, 6950, 10.1158/0008-5472.CAN-04-0677 Xiao, 2016, Cancer-associated fibroblasts in pancreatic cancer are reprogrammed by tumor-induced alterations in genomic DNA methylation, Cancer Res, 76, 5395, 10.1158/0008-5472.CAN-15-3264 Zheng, 2018, Immune defects in pancreatic cancer, Ann Pancreat Cancer, 1, 33, 10.21037/apc.2018.11.01 Neuzillet, 2019, Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma, J Pathol, 248, 51, 10.1002/path.5224 Biffi, 2019, IL1-induced JAK/STAT signaling is antagonized by TGFβ to shape CAF heterogeneity in pancreatic ductal adenocarcinoma, Cancer Discov, 9, 282, 10.1158/2159-8290.CD-18-0710 Rucki, 2017, Heterogeneous stromal signaling within the tumor microenvironment controls the metastasis of pancreatic cancer, Cancer Res, 77, 41, 10.1158/0008-5472.CAN-16-1383 Öhlund, 2017, Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer, J Exp Med, 214, 579, 10.1084/jem.20162024 Le, 2017, Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade, Science, 357, 409, 10.1126/science.aan6733 Shindo, 2017, Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma, J Clin Oncol, 35, 3382, 10.1200/JCO.2017.72.3502 Aguirre, 2017, Advances in the genetics and biology of pancreatic cancer, Cancer J, 23, 315, 10.1097/PPO.0000000000000286 Waddell, 2015, Whole genomes redefine the mutational landscape of pancreatic cancer, Nature, 518, 495, 10.1038/nature14169 Lowery, 2018, Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms, J Natl Cancer Inst, 110, 1067, 10.1093/jnci/djy024 Pishvaian, 2018, Molecular profiling of patients with pancreatic cancer: initial results from the know your tumor initiative, Clin Cancer Res, 24, 5018, 10.1158/1078-0432.CCR-18-2645 Lowery, 2017, Real-time genomic profiling of pancreatic ductal adenocarcinoma: potential actionability and correlation with clinical phenotype, Clin Cancer Res, 23, 6094, 10.1158/1078-0432.CCR-17-0899 Kamel, 2018, PARP inhibitor drugs in the treatment of breast, ovarian, prostate and pancreatic cancers: an update of clinical trials, Curr Drug Targets, 19, 21, 10.2174/1389450118666170711151518 Bhalla, 2014, PARP-inhibitors in BRCA-associated pancreatic cancer, JOP, 15, 340 Yarchoan, 2017, Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer, Oncotarget, 8, 44073, 10.18632/oncotarget.17237 Lowery, 2018, Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma, Eur J Cancer, 89, 19, 10.1016/j.ejca.2017.11.004 de Bono, 2017, Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers, Cancer Discov, 7, 620, 10.1158/2159-8290.CD-16-1250 Golan, 2019, Maintenance olaparib for germline BRCA-mutatedmetastatic pancreatic cancer, N Engl J Med, 10.1056/NEJMoa1903387 Blair, 2018, BRCA1/BRCA2 germline mutation carriers and sporadic pancreatic ductal adenocarcinoma, J Am Coll Surg, 226, 630, 10.1016/j.jamcollsurg.2017.12.021 Balachandran, 2017, Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer, Nature, 551, 512, 10.1038/nature24462 Mateo, 2018, A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), Ann Oncol, 29, 1895, 10.1093/annonc/mdy263 Mishra, 2019, Discovery of a novel DNA polymerase inhibitor and characterization of its antiproliferative properties, Cancer Biol Ther, 20, 474, 10.1080/15384047.2018.1529126 Gall, 2019, Circulating tumor cells and cell-free DNA in pancreatic ductal adenocarcinoma, Am J Pathol, 189, 71, 10.1016/j.ajpath.2018.03.020 Perales-Patón, 2017, Pancreas cancer precision treatment using avatar mice from a bioinformatics perspective, Public Health Genomics, 20, 81, 10.1159/000479812 Tiriac, 2019, Organoid models for translational pancreatic cancer research, Curr Opin Genet Dev, 54, 7, 10.1016/j.gde.2019.02.003